Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUARTETTE vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
FDA-approved for the prevention of pregnancy in women with type 2 diabetes mellitus or at risk for type 2 diabetes,Off-label: Management of polycystic ovary syndrome (PCOS), acne vulgaris, hirsutism, and menstrual irregularities
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
3 mg orally once daily for 21 days followed by 7 days of placebo.
400 mg orally once daily with food.
Terminal elimination half-life is 12-14 hours; clinically this supports once-daily dosing with steady state achieved within 2-3 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Drospirenone: CYP3A4-mediated metabolism; ethinyl estradiol: primarily CYP3A4; metformin: not metabolized (excreted unchanged in urine); levomefolate calcium: converted to active folate via dihydrofolate reductase and other enzymes.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal excretion accounts for 55% (primarily as unchanged drug), biliary/fecal excretion 35%, and the remainder undergoes metabolic clearance.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
92% bound to albumin and alpha-1-acid glycoprotein.
98% bound to albumin
Vd = 0.8-1.0 L/kg, indicating extensive tissue distribution (total body water plus some tissue binding).
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 80-90% (first-pass metabolism minimal); intravenous: 100%.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Not recommended for severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not established for patients under 18 years of age.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
No specific dose adjustment recommended. Use with caution due to potential for decreased renal function.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Warning: Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Risk of thromboembolic disorders, especially in smokers and women over 35; lactic acidosis associated with metformin, especially in renal impairment; hyperkalemia due to drospirenone's antimineralocorticoid effect; vitamin B12 deficiency with long-term metformin use; and folate supplementation risks in patients with vitamin B12 deficiency.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir; renal impairment (Cr Cl <60 m L/min for metformin); acute or chronic metabolic acidosis including diabetic ketoacidosis; liver disease or tumors; history of or current thromboembolic disorders; known or suspected pregnancy; undiagnosed abnormal uterine bleeding; hypersensitivity to any component.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific dietary restrictions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Advise consistent intake to avoid absorption variability.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
QUARTETTE is a combined hormonal contraceptive pill. In early pregnancy, exposure does not increase risk of major malformations. No known risk in first trimester; contraindicated in pregnancy due to lack of need and potential hormonal effects. Second and third trimester exposure is not applicable as pregnancy excludes use; no fetal risks reported from accidental exposure.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted into breast milk in small amounts. Estrogen may reduce milk production and composition; use postpartum only after established lactation (6+ weeks). M/P ratio not established. Use alternative contraception during breastfeeding if possible.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment exists as use is avoided.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
QUARTETTE is a combined hormonal contraceptive containing ethinyl estradiol and levonorgestrel, with a unique 4-day placebo phase (91-day cycle) to extend menstrual suppression. For patients with breakthrough bleeding, consider shorter placebo intervals or continuous use. Assess venous thromboembolism risk factors before prescribing, especially in smokers over 35. Counsel on delayed start if initiating after day 5 of menses.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time; missed pills increase pregnancy risk.,Use backup contraception (e.g., condoms) for the first 7 days if starting after day 5 of menses.,Expect lighter, less frequent periods; spotting may occur initially.,Do not skip the 4 placebo pills; they are reminder pills.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUARTETTE vs ADQUEY, answered by our medical review team.
QUARTETTE is a Oral Contraceptive that works by Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUARTETTE and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUARTETTE is: 3 mg orally once daily for 21 days followed by 7 days of placebo.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUARTETTE and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUARTETTE is classified as Category C. QUARTETTE is a combined hormonal contraceptive pill. In early pregnancy, exposure does not increase risk of major malformations. No known risk in first trimester; contraindicated i. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.